The medical device industry is full of companies that started out focusing on one therapeutic area only to shift gears and apply their original or another technooloogy to a different clinical need. Indeed, Biocompatibles is now workiing on its third primary therapeutic areas--cancer--having previously sold off its first two businesses, in ophthalmology and then, convinced it was too far behind in drug-eluting stents, cardiovascular. This new growth area is being driven by the company's general expertise in polymer technology and drug delivery.
By Stephen Levin
The medical device industry is full of companies that started out focusing on one therapeutic area only to shift gears...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.
Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.
The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Astellas is transforming its oncology drug discovery using its human-in-the-loop approach which positions AI as a true partner in innovation.
A new AI-based platform is designed to condense months of clinical data analysis into minutes by translating plain language data queries into epidemiologically valid research requests.
Emerging research reveals that biological sex differences may significantly influence Alzheimer’s disease progression and treatment efficacy, underscoring the urgent need for sex-specific analysis in clinical trials and therapeutic development.
